NATERA INC (NTRA)
US6323071042 - Common Stock
We assign a fundamental rating of 3 out of 10 to NTRA. NTRA was compared to 588 industry peers in the Biotechnology industry. The financial health of NTRA is average, but there are quite some concerns on its profitability. NTRA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year NTRA has reported negative net income.
In the past year NTRA has reported a negative cash flow from operations.
In the past 5 years NTRA always reported negative net income.
In the past 5 years NTRA always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of NTRA (-30.15%) is better than 73.21% of its industry peers.
NTRA has a better Return On Equity (-56.80%) than 63.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.15% | ||
| ROE | -56.8% | ||
| ROIC | N/A |
ROA(3y)-35.86%
ROA(5y)-30.73%
ROE(3y)-68.88%
ROE(5y)-59.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 45.52%, NTRA is in the better half of the industry, outperforming 79.69% of the companies in the same industry.
In the last couple of years the Gross Margin of NTRA has grown nicely.
NTRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y5.07%
2. Health
2.1 Basic Checks
NTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NTRA has more shares outstanding
NTRA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NTRA has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 8.29 indicates that NTRA is not in any danger for bankruptcy at the moment.
NTRA has a Altman-Z score of 8.29. This is amongst the best in the industry. NTRA outperforms 85.15% of its industry peers.
NTRA has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
NTRA has a Debt to Equity ratio of 0.47. This is in the lower half of the industry: NTRA underperforms 72.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.29 |
ROIC/WACCN/A
WACC9.06%
2.3 Liquidity
A Current Ratio of 4.10 indicates that NTRA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.10, NTRA is in line with its industry, outperforming 46.08% of the companies in the same industry.
A Quick Ratio of 3.96 indicates that NTRA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.96, NTRA is in line with its industry, outperforming 45.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.1 | ||
| Quick Ratio | 3.96 |
3. Growth
3.1 Past
NTRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.96%, which is quite impressive.
Looking at the last year, NTRA shows a very strong growth in Revenue. The Revenue has grown by 31.99%.
The Revenue has been growing by 33.25% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)31.96%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q53.28%
Revenue 1Y (TTM)31.99%
Revenue growth 3Y40.42%
Revenue growth 5Y33.25%
Revenue growth Q2Q43.17%
3.2 Future
The Earnings Per Share is expected to grow by 24.56% on average over the next years. This is a very strong growth
NTRA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.40% yearly.
EPS Next Y37.44%
EPS Next 2Y29.39%
EPS Next 3Y24.56%
EPS Next 5YN/A
Revenue Next Year26.81%
Revenue Next 2Y22.17%
Revenue Next 3Y19.92%
Revenue Next 5Y18.4%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NTRA. In the last year negative earnings were reported.
Also next year NTRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NTRA's earnings are expected to grow with 24.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.39%
EPS Next 3Y24.56%
5. Dividend
5.1 Amount
NTRA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NATERA INC
NASDAQ:NTRA (4/30/2024, 7:15:09 PM)
After market: 92.88 0 (0%)92.88
-1.16 (-1.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap11.22B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.15% | ||
| ROE | -56.8% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.52% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.1 | ||
| Quick Ratio | 3.96 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)31.96%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y37.44%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)31.99%
Revenue growth 3Y40.42%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y